Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

<< Previous

Bullboard Posts

Next >>

Post by Oden6570on Dec 15, 2024 5:14am

259 Views

Post# 36362864

Over 1 in 5 adults worldwide has a genital herpes infection

Over 1 in 5 adults worldwide has a genital herpes infection – WHO

Kevin Coombs, Ph.D., Professor, Medical Microbiology, University of Manitoba stated, “My team and I were excited by the results we have obtained as we have worked with several anti-viral compounds over the years and have found that Ruvidar^TM is far more potent than any of the others we have worked with, in fact Ruvidar^TM is effective at concentrations approximately 100-fold lower than those we have previously tested. I believe Ruvidar^TM has the potential to be effective as a broad-spectrum viral vaccine able to mitigate the biothreat of various emerging infectious disease pathogens. In our research, we found that nanomolar and micromolar concentrations of Ruvidar^TMwere all that was required in order to inactivate 90 to 99.9% of all seven viruses that we tested, including H1N1 influenza virus, coronavirus, Zika virus, poxvirus and herpes virus. In fact, Ruvidar^TMat 3 mM completely killed the herpes virus.”

Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus | Nasdaq

Roger DuMoulin-White, B.E.Sc., P.Eng., Pro.Dir., President and Chief Executive Officer of Theralase® stated, " This latest research continues to strengthen what we already know, Ruvidar™ is a very potent drug in the destruction of cancer, viruses and bacteria on its own and is further enhanced by light, radiation, sound or drug activation. Based on this latest research, Theralase® plans to commence seeking a partner / licensing opportunity in the development of Ruvidar™ for both a topical and oral treatment for the prevention and treatment of herpes simplex. "

Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus | Nasdaq

<< Previous

Bullboard Posts

Next >>

Arctic Wolf to acquire BlackBerry’s Cylance endpoint security assets